Alectinib

What is Alectinib?

Alectinib is a prescription medication used to treat specific types of lung cancer. It is a highly selective anaplastic lymphoma kinase (ALK) inhibitor, approved for patients with non-small cell lung cancer (NSCLC) that is ALK-positive. As a targeted therapy, Alectinib works by interfering with particular molecules essential for cancer growth, distinguishing it from traditional chemotherapy. This precise approach is vital for patients whose tumors exhibit this specific genetic alteration, offering a more personalized treatment strategy.

How Does it Work?

Alectinib's mechanism involves inhibiting the anaplastic lymphoma kinase (ALK) enzyme. In certain NSCLC cases, an ALK gene rearrangement leads to an abnormal ALK fusion protein, which signals cancer cells to grow uncontrollably. This abnormal protein acts as a constitutively active tyrosine kinase inhibitor. Alectinib binds to and inhibits this abnormal protein, blocking the signaling pathways that drive cancer cell proliferation and inducing cell death. A key advantage is its ability to cross the blood-brain barrier, making it effective against brain metastases, a common complication in ALK-positive NSCLC.

Medical Uses

Alectinib's primary use is for ALK-positive metastatic non-small cell lung cancer. It is indicated for:

• First-line treatment: For patients with ALK-positive metastatic NSCLC who have not previously received an ALK inhibitor. It has shown superior efficacy, improving progression-free survival.
• Previously treated patients: For those who have progressed on or are intolerant to crizotinib, another ALK inhibitor. Alectinib offers continued disease control, often effective against central nervous system (CNS) metastases.

Tumor testing for ALK gene rearrangements is essential before starting Alectinib to ensure appropriate patient selection.

Dosage

Alectinib is taken orally as capsules, typically 600 mg twice daily with food. Adherence to your healthcare provider's prescription is crucial; do not alter the dose or frequency. If a dose is missed, take it as soon as remembered, unless it's nearly time for the next dose. Never double up. Your doctor may adjust the dose based on your response and any experienced side effects, particularly if you develop severe liver enzyme elevations, bradycardia, or muscle pain. Always follow prescribing information and discuss concerns with your healthcare team.

Side Effects

Like all medications, Alectinib can cause side effects. Common ones include fatigue, constipation, muscle pain (myalgia), swelling (edema) in the hands/feet, anemia, weight gain, and changes in liver enzyme levels. More serious, though less common, side effects include severe liver problems, interstitial lung disease, severe muscle pain/weakness with elevated CPK, kidney impairment, and severe bradycardia. Report any new or worsening symptoms to your doctor immediately. Regular blood tests will monitor liver, muscle, and kidney function during treatment.

Drug Interactions

Inform your doctor and pharmacist about all current medications, including OTC drugs, vitamins, and herbal supplements. Alectinib can interact with other substances. Key drug interactions:

• Strong CYP3A inhibitors: Can increase Alectinib levels, potentially increasing side effects (e.g., ketoconazole, grapefruit juice).
• Strong CYP3A inducers: Can decrease Alectinib levels, reducing effectiveness (e.g., rifampin, St. John's Wort).
• Drugs causing bradycardia: Use with caution, as Alectinib can also slow heart rate.

Always consult your healthcare provider before starting or stopping any new medication.

FAQ

Is Alectinib a chemotherapy drug?

No, Alectinib is a targeted therapy, specifically an ALK inhibitor, not traditional chemotherapy. It precisely attacks cancer cells by interfering with specific molecular pathways, leading to a different side effect profile than chemotherapy.

How long do patients typically take Alectinib?

Treatment continues as long as the patient benefits and tolerates the medication, which can range from months to years. The decision to continue or discontinue is made by the physician based on disease progression and patient health.

What does "ALK-positive" mean in NSCLC?

"ALK-positive" signifies a specific genetic abnormality in non-small cell lung cancer cells: a rearrangement of the ALK gene. This leads to an abnormal ALK fusion protein that drives cancer growth. Identifying this is crucial because it indicates the cancer will likely respond to ALK inhibitors like Alectinib.

Can Alectinib cure lung cancer?

While highly effective in controlling ALK-positive NSCLC, extending survival, and improving quality of life, Alectinib is generally not considered a cure for metastatic lung cancer. The goal is typically long-term disease control and management.

Products containing Alectinib are available through trusted online pharmacies. You can browse Alectinib-based medications at ShipperVIP or Medicenter.

Summary

Alectinib represents a significant therapeutic advance for patients with ALK-positive non-small cell lung cancer. As a potent and selective ALK kinase inhibitor, it offers a targeted approach, blocking cancer cell growth and often effective against brain metastases. Understanding its mechanism, uses, dosage, potential side effects, and drug interactions is crucial. While not a cure, Alectinib is vital for long-term disease management, improving outcomes and quality of life. Always consult a healthcare professional for personalized medical advice.